Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18781586 | 0.85 | CYP1A2 (0.53) | CYP1A2TRPV1PDGFRBPDGFRAMGAM | |
| SCHEMBL28087554 | 0.85 | CYP1A2 (0.53) | CYP1A2TRPV1PDGFRBPDGFRAMGAM | |
| SCHEMBL24604914 | 0.84 | MAPT (0.45) | CYP1A2TRPV1PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL22023686 | 0.82 | CYP1A2 (0.50) | CYP1A2TRPV1PDGFRBPDGFRAMGAM | |
| SCHEMBL2633082 | 0.82 | CYP1A2 (0.50) | CYP1A2TRPV1PDGFRBPDGFRAMGAM | |
| SCHEMBL27536533 | 0.82 | CYP1A2 (0.53) | CYP1A2TRPV1PDGFRBPDGFRAMGAM | |
| SCHEMBL4548632 | 0.82 | SCN10A (0.42) | CYP1A2TRPV1ALDH1A1MAPTHPGD | |
| SCHEMBL29378132 | 0.80 | PDGFRB (0.60) | CYP1A2TRPV1PDGFRBPDGFRACYP2A6 | |
| SCHEMBL12187804 | 0.80 | CYP1A2 (0.49) | CYP1A2TRPV1PDGFRBPDGFRAMGAM | |
| SCHEMBL1695518 | 0.80 | TRPV1 (0.40) | CYP1A2TRPV1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-7276348-B2 | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070135418-A1 | Compositions and methods relating to novel compounds and targets thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-06-14 | — | — | US | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CYP1A2 827/4885TRPV1 2312/4885PDGFRB 2689/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | CYP1A2 380/4885TRPV1 3623/4885PDGFRB 3217/4885 |
| US-20070135418-A1 | Compositions and methods relating to novel compounds and targets thereof | BAX, BAD, GABRB3 | CYP1A2 1408/4885TRPV1 323/4885PDGFRB 1366/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | CYP1A2 298/4885TRPV1 215/4885PDGFRB 664/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | CYP1A2 2627/4885TRPV1 4289/4885PDGFRB 31/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3324/4885TRPV1 4248/4885PDGFRB 3830/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | CYP1A2 398/4885TRPV1 2815/4885PDGFRB 4229/4885 |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | GABRA5, GABRA3, GABRA6 | CYP1A2 48/4885TRPV1 559/4885PDGFRB 3966/4885 |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | CYP1A2 211/4885TRPV1 5/4885PDGFRB 397/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CYP1A2 50/4885TRPV1 827/4885PDGFRB 3336/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | CYP1A2 1791/4885TRPV1 4789/4885PDGFRB 3396/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | CYP1A2 486/4885TRPV1 131/4885PDGFRB 424/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP1A2 4271/4885TRPV1 4779/4885PDGFRB 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.